Skip to content
Journal article

Endometrial cancer

C. H...(+1 more)

Poloznictwo Ginekologia i Medycyna Rozrodu, vol. 3, issue 1 (2009) pp. 52-60

  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
  • N/A


    ScienceDirect users who have downloaded this article.
Sign in to save reference


The incidence of endometrial cancer is increasing. The overall 5-year survival rate is high, reflecting early presentation in most cases, but outcomes for advanced disease remain poor. Surgery for low-risk disease may be undertaken by general gynaecologists, but all patients require specialist multidisciplinary input. The cornerstone of treatment remains surgery, and laparoscopic surgery is emerging as a means of reducing morbidity. Systematic lymphadenectomy in all cases is unjustified, and adjuvant radiotherapy is now given only to selected patients at high risk of recurrence. Chemotherapy is increasingly used in high-risk and advanced disease, although the optimum drug combination is unclear. Future developments are likely to include the emergence of molecularly targeted therapies as an addition to existing treatments and the possibility of fertility-sparing hormonal treatments in selected patients. (copyright) 2007 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • adjuvant therapy
  • antineoplastic agent
  • brachytherapy
  • cancer chemotherapy
  • cancer diagnosis
  • cancer hormone therapy
  • cancer incidence
  • cancer radiotherapy
  • cancer surgery
  • carboplatin
  • cisplatin
  • clinical feature
  • clinical trial
  • computer assisted tomography
  • doxorubicin
  • endometrium biopsy
  • endometrium cancer
  • fluorodeoxyglucose f 18
  • gynecology
  • histopathology
  • human
  • laparoscopic surgery
  • lymph node dissection
  • nuclear magnetic resonance imaging
  • overall survival
  • paclitaxel
  • positron emission tomography
  • review
  • tamoxifen

Cite this document

Choose a citation style from the tabs below